Currently, there are 113.40M common shares owned by the public and among those 107.98M shares have been available to trade.
Insiders at the company have transacted a total of 62 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 31 of these insider trades were purchases, accounting for 585,559 shares. Insider sales of the common stock occurred on 31 occasions, with total insider shares sold totaling 518,514 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the script later moved the day high at 32.23, up 25.38%. The company’s stock has a 5-day price change of 35.00% and 116.76% over the past three months. CBAY shares are trading 36.37% year to date (YTD), with the 12-month market performance up to 281.18% higher. It has a 12-month low price of $7.26 and touched a high of $26.35 over the same period. CBAY has an average intraday trading volume of 41.66 shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 34.83%, 40.92%, and 111.19% respectively.
Institutional ownership of Cymabay Therapeutics Inc (NASDAQ: CBAY) shares accounts for 95.48% of the company’s 113.40M shares outstanding.
It has a market capitalization of $3.65B and a beta (3y monthly) value of 0.25. The earnings-per-share (ttm) stands at -$0.93. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.16% over the week and 4.53% over the month.
Analysts forecast that Cymabay Therapeutics Inc (CBAY) will achieve an EPS of -$0.31 for the current quarter, -$0.32 for the next quarter and -$1.38 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.35 while analysts give the company a high EPS estimate of -$0.26. Comparatively, EPS for the current quarter was -$0.3 a year ago. Earnings per share for the fiscal year are expected to increase by 21.90%, and -45.84% over the next financial year.
Looking at the support for the CBAY, a number of firms have released research notes about the stock. UBS stated their Buy rating for the stock in a research note on August 14, 2023, with the firm’s price target at $18.
